Today Pfizer announced they plan to “to extend their rolling submission to the U.S. Food and Drug Administration (FDA) seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine to include children 6 months through 4 years of age, which had been requested by FDA.”
Two doses failed to provide protection. Pfizer says they will wait until they have results from a third dose being given in their clinical trial before they move forward and ask the FDA for Emergency Use Authorization for the age group. They estimate they will have trial results by early April.
As of this writing, the February 15 FDA Meeting is still showing on their calendar, and you can still provide comment to the Federal Register . Please keep your comments flowing to the FDA, the CDC, your legislators, doctors, and more. Public pressure is impacting decisions at all levels.
